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Abstract
Studies have demonstrated that intensive ART alone is not capable of eradicating HIV-1, as
the virus rebounds within a few weeks upon treatment interruption. Viral rebound may be
induced from several cellular subsets; however, the majority of proviral DNA has been found
in antigen experienced resting CD4+ T cells. To achieve a cure for HIV-1, eradication strate-
gies depend upon both understanding mechanisms that drive HIV-1 persistence as well as
sensitive assays to measure the frequency of infected cells after therapeutic interventions.
Assays such as the quantitative viral outgrowth assay (QVOA) measure HIV-1 persistence
during ART by ex vivo activation of resting CD4+ T cells to induce latency reversal; however,
recent studies have shown that only a fraction of replication-competent viruses are inducible
by primary mitogen stimulation. Previous studies have shown a correlation between the
acquisition of effector memory phenotype and HIV-1 latency reversal in quiescent CD4+ T
cell subsets that harbor the reservoir. Here, we apply our mechanistic understanding that
differentiation into effector memory CD4+ T cells more effectively promotes HIV-1 latency
reversal to significantly improve proviral measurements in the QVOA, termed differentiation
QVOA (dQVOA), which reveals a significantly higher frequency of the inducible HIV-1 repli-
cation-competent reservoir in resting CD4+ T cells.
Author summary
Quantifying the number of cells harboring HIV-1 provirus is critical to evaluating HIV
cure interventions, but precise quantification of the latent reservoir has proven to be
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technically challenging. Our data demonstrates that targeted differentiation of CD4+ T
cells to an effector memory phenotype is a successful strategy for promoting latency rever-
sal in vitro, and significantly enhances the performance of existing protocols to quantify
the frequency of replication-competent HIV-1 in resting CD4+ T cells from virally-sup-
pressed individuals. Using peripheral blood samples from well-established and character-
ized cohorts, we show the presence of a significantly higher frequency of replication-
competent provirus than has previously been reported, raising the average estimated fre-
quency 18-fold over the established QVOA measures. These results demonstrate that ex
vivo effector memory differentiation has moved reservoir measurements closer to what
may be the bona fide inducible replication-competent reservoir frequency, thus beginning
to bridge the gap between viral outgrowth and molecular-based quantification. Taken
together, these data support accumulating evidence that effector memory differentiation
is a key pathway to HIV-1 latency reversal that may be exploited for assay development,
mechanistic understanding, and therapeutic interventions.
Introduction
ART suppresses HIV-1 replication to undetectable levels but cannot eliminate the virus due to
early establishment of a persistent reservoir of latently infected cells that provides a long-lived
source of rebound viremia [1–4]. The mechanisms that govern latency reversal and viral
rebound in vivo are still being defined, including the elucidation of the cellular compartments
that contribute to HIV-1 reactivation after ART interruption [5–12]. Understanding the mech-
anisms that maintain or reverse latency in vivo is critical for the success of therapeutic strate-
gies aimed at supporting viral remission, controlled treatment interruption, or cure.
Viral rebound may originate from several cellular subsets, including naive CD4+ T cells
and myeloid cells; however, the majority of proviral HIV-1 DNA persists in CD4+ T cells dis-
playing a memory phenotype, which include central (TCM), transitional (TTM) and effector
(TEM) memory subsets that are each endowed with distinct phenotypic and functional proper-
ties and can persist for decades [13–19]. The latent reservoir frequency has been estimated to
be approximately one in one million resting CD4+ T cells but can be highly variable among
successfully treated individuals [20]; influenced by the nadir CD4+ T cell count [21], the CD4/
CD8 ratio [22], the time between infection and initiation of ART [13] and the total time on
ART [23]. Quantification of the frequency of cells with intact provirus is a critical component
in understanding HIV pathogenesis under ART, as well as the ability to evaluate therapeutic
cure strategies to eliminate the latent reservoir. A number of approaches have been developed
to quantify the HIV-1 reservoir from ex vivo peripheral blood (reviewed in [24]), including
molecular based assays to quantify cell-associated HIV-1 RNA [25–27] or HIV-1 DNA fre-
quencies [28–33] or both [34], along with assays that specifically assess the replication-compe-
tent reservoir through quantitative viral outgrowth [5, 23, 32, 35–39]. Importantly, reservoir
quantification approaches to date have shown advantages as well as limitations relating to
either over or under estimation of the replication-competent reservoir size, the inability to dis-
tinguish intact versus defective proviruses, or low throughput for clinical applications.
Another significant challenge inherent in these assays is the translation of ex vivo measure-
ments to the replication-competent reservoir that may be inducible in vivo, both in the context
of viral rebound after treatment interruption as well as during targeted latency reversal as a
therapeutic intervention. Multiple studies have identified pathways that support HIV latency
reversal in CD4+ T cells, including activation of protein kinase C, NFAT, and NF-KB signaling
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as well as changes in epigenetic modifiers [40–42]. Expression of these pathways is associated
with cellular activation, and have been shown to support HIV-1 latency reversal in vitro [40,
43–46]. However, several studies have demonstrated that cellular activation alone may not be
sufficient to induce latency reversal from a signficant proportion of replication-competent
proviruses from virally suppressed individuals [47, 48]. Indeed, recent data suggest a role for
the acquistion of effector function as a pathway to more effective HIV-1 latency reversal in
memory CD4+ T cells [49]. Differentiation of memory CD4+ T cells results in the acquistion
of effector function, including effector cytokine production (IFN-γ, TNF-α, IL-2), and also
includes the upregulation of activation markers (CD38, CD69, IL2Rα/CD25), transcription
factors known to activate HIV-1 (NFAT, STAT5, NF-KB, E2), and the translation apparatus
(EIF2S1, EIF4A1; [50–53]; reviewed in [54–56]). Effector memory differentiation also leads to
changes in the machinery controlling epigenetic modulation, such as histone deacetylases
(HDAC1, HDAC3, HDAC4, HDAC8, HDAC9) and the chromatin remodeling complex
(SMARCAL1, SMARCD1, SMARCE1) [57–63]. As expected, these changes in gene expression
correlate with and predict HIV-1 latency reversal in quiescent CD4+ T cell subsets like TCM
[49]. However, these studies were performed employing assays like TILDA, which quantifies
the frequency of the inducible reservoir by measuring multi-spliced HIV RNA expression in
mitogen activated total CD4+ T cells as a surrogate for virus production [64]. The observed
correlation between the acquisition of an effector memory phenotype and HIV-1 latency
reversal led us to hypothesize that effector memory polarization is an efficient pathway to
latency reversal of replication-competent HIV-1 in lymphoid reservoirs. To test this hypothe-
sis, we examined the impact of effector memory differentiation in ex vivo resting CD4+ T cells
in the context of the quantitative viral outgrowth assay (QVOA).
Results
Effector memory differentiation enhances latency reversal of the
replication-competent reservoir
To characterize the impact of effector memory differentiation on induction and outgrowth of
replication-competent HIV-1 in resting CD4+ T cells in the context of the QVOA [36], we
employed a combination of γ-chain (IL-7, IL-15) and dendritic cell (DC)-derived (IL-6, IL-10,
TNF-α) cytokines previously established to polarize memory CD4+ T cells to acquire effector
function and downregulate chemokine receptor CCR7 (Fig 1A; [65]). Initially, resting CD4+ T
cells (rCD4+) were enriched from cryopreserved PBMCs from 12 virally suppressed research
study participants (Table 1), 10 from the RAVEN cohort (median time of suppression 14.5
years, range 10.4–19.3) and 2 from an NIH cohort (median time of suppression 16.5 years,
range 16.1–16.8), and the proportion of cells in the naïve compartment and each memory
CD4+ T cell subset (TCM, TTM, and TEM) including the terminally differentiated TEM subset
that has re-gained CD45RA expression (TEMRA) was determined (Fig 1B and 1C).
Due to the fact that differentiation cytokines may induce proliferation that result in expan-
sion or redistribution of the HIV-infected cell population, rCD4+ were distributed in limiting
dilution at assay initiation, prior to all differentiation and stimulation steps (Fig 1A). Once
plated in limiting dilution, the cells were never redistributed at any other point in the assay,
thus preserving the original frequency of intact provirus for maximum likelihood calculations.
Cells in limiting dilution (5x105, 2x105, 4x104 and 8x103 cells/well; S1 Table) were cultured in
the differentiation cytokines for 7 days (Fig 1A). After differentiation culture, one well of the
rCD4+ T cells was assessed to monitor for changes in CD45RA, CCR7, CD27 and IL-2Rα
(CD25) expression by flow cytometry (Fig 1B). Naïve CD4+ T cells (mean fold-change based
on relative percentages = 0.83±0.19; p value = 0.0195) along with the TCM (mean fold-
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change = 0.69±0.20; p value = 0.0039), TTM (mean fold-change = 0.85±0.38; p value = 0.0195)
and TEMRA (mean fold-change = 0.26±0.22; p value = 0.002) subsets all showed a significant
decrease in frequency after differentiation culture, while the TEM (mean fold-change = 2.52
±1.29; p value = 0.0098) showed a significant increase (Fig 1B and 1C). The proportion of cells
expressing IL-2Rα (CD25), induced by exposure to DC-derived cytokines, was significantly
increased in naïve, TCM, TTM, and TEM (S1A Fig). After differentiation culture, rCD4+ T cells
were maintained in their original limiting dilution distribution and IL-2 and the mitogen
phytohemagglutinin (PHA) were added. IL-2 plus PHA activation was performed in the pres-
ence of γ-irradiated allogeneic PBMCs at a ratio of 1:10 as previously described [36] and cul-
tures were maintained for an additional 11 days. For viral outgrowth, the participant’s own
differentiated and activated CD4+ T cells readily expanded the replication-competent reser-
voir, eliminating the need for addition of allogenic donor lymphoblasts as target cells that may
confound replication dynamics and consequent IUPM frequency. Indeed, Geginat et al.
showed previously that differentiation of TCM into TEM results in polarization toward Th1 and
Th2 phenotypes and increased surface expression of CCR5, an HIV co-receptor that may
enhance the ability of the differentiated CD4 T cells to propagate virus [65]; similar post-differ-
entiation IFN-γ and IL-4 production and upregulation of CCR5 were confirmed using samples
from HIV-infected participants 2147-R, 2511-R, and 2185-R (S1B Fig). As a control for
Fig 1. Ex vivo differentiation of resting enriched CD4+ T cells prior to QVOA increases detectable reactivation of latent HIV-1. a, Schematic of assay outline for
QVOA and differentiation QVOA (dQVOA). The relative distribution of central memory (TCM), effector memory (TEM), and transitional memory (TTM) cells during
each phase of the assays are represented as blue, orange, and green characters. b, Flow cytometric analysis showing the memory T cell subset gating strategy on samples
from RAVEN participant 2274-R either after resting enrichment (top panel, cells that enter QVOA) or after 7 days of differentiation (bottom panel, cells that enter
dQVOA). The numbers in each gate represent the percentage of events arising from its parental population. c, Column plot showing the proportions of naïve, TCM,
TTM, TEM and TEMRA cells as a percentage of live CD3+Lineage-CD8- lymphocytes before and after 7 days of differentiation. NIH 2–20 and NIH 2–37 were assessed for
memory subset distribution using a different flow cytometry antibody panel compared to the RAVEN participant samples and therefore were not included in this
analysis. d, XY plots showing HIV-1-Gag expression level in each well from QVOA (top panel) and dQVOA (bottom panels) over time. The rCD4+ T cell source was
RAVEN participant 2147-R. Stimulation was performed on day 0 for QVOA and dQVOA and when noted ART (EFV/RAL) was included in all media in the assay.
Limiting dilutions performed for each assay type are shown. e, Bar graph showing the proportions of QVOA wells (black) found to be HIV-1-Gag+ compared to
dQVOA wells (grey). f, Column graph showing the latent HIV-1 reservoir measured as infectious units per million rCD4+ T cells (IUPM) through QVOA and
dQVOA. Limit of detection for each assay is represented by red bars. Wilcoxon matched-pairs signed rank tests were used and � denotes p< 0.05, �� denotes p< 0.01,
and ��� denotes p< 0.001.
https://doi.org/10.1371/journal.ppat.1008074.g001
Table 1. HIV-Infected participant characteristics.




ART regimen at time of collection Minimum length of viral suppression (Years)
NIH 2–20 65 M 638 <40 ABC/3TC/DTG 16.1
NIH 2–37 62 M 792 <40 TDF/FTC/RAL 16.8
2147-R 59 M 497 <40 RPV/TDF/FTC 11.6
2026-R 61 M 366 <40 ABC/DTG/3TC 15.1
3068-R 62 M 472 <40 ABC/3TC, ETV, RAL 14.1
2046-R 51 M 747 <40 ECV, EFV/TDF/FTC 17.0
2044-R 65 M 486 <40 ABC/3TC, DTG 16.4
2461-R 62 M 667 <40 DTG, RPV 16.2
2511-R 48 M 397 <40 EFV/TDF/FTC, RAL 10.4
2013-R 68 M 634 <40 ABC/3TC, RAL 19.3
2185-R 59 M 624 <40 EFV/TDF/FTC 12.3
2274-R 55 M 344 <40 NVP, FTC/TDF 13.1
Clinical characteristics of participants from the NIH or RAVEN (-R) cohort are shown. Abbreviations: 3TC–lamivudine, ABC–abacavir, DTG–dolutegravir, ECV—
entecavir, EFV–efavirenz, ETV–etravirine, FTC–emtricitabine, NVP–nevirapine, RAL–raltegravir, TDF–tenofovir disproxil fumarate.
https://doi.org/10.1371/journal.ppat.1008074.t001
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effector memory polarization on priming resting CD4+ T cells for induction of replication-
competent HIV-1 expression, rCD4+ T cells from the same participants were cultured in par-
allel after distribution in limiting dilution (1x106, 2x105, 4x104 cells/well; S1 Table) with PHA
plus IL-2 activation using the classical QVOA procedure previously described (Fig 1A; [36]).
Per published protocol, control QVOA cultures also included the addition of γ-irradiated allo-
geneic PBMCs as well as activated allogeneic lymphoblasts as permissive targets for HIV-1
expansion [36]. Culture supernatants from individual wells from both the QVOA and differen-
tiation culture QVOA (dQVOA) were collected and assessed for outgrowth of replication-
competent HIV-1 by scoring for the exponential increase in supernatant HIV-1-Gag expres-
sion by p24 ELISA (Fig 1D). By inducing effector memory differentiation, we found the fre-
quency of HIV-1-Gag+ wells detected was greatly increased from each participant across all
dilutions (Fig 1D and 1E; S1 Table), resulting in an average 18-fold increase in the calculated
frequency of Infectious Units Per Million rCD4+ T cells (IUPM; [66]) evaluated by dQVOA
(5.203 mean IUPM) over control QVOA (0.729 mean IUPM; Fig 1F; S1 Table). The magnitude
and kinetics of HIV-1-Gag detection in positive culture wells demonstrated evidence of repli-
cation-competent virus outgrowth in both QVOA and dQVOA (Fig 1D). Replication compe-
tence was further verified by including the non-nucleoside reverse transcriptase inhibitor
efavirenz (EFV) and integrase strand-transfer inhibitor raltegravir (RAL) in dQVOA and
monitoring the culture supernatant in each well over time (Fig 1D). We found no detectable
HIV-1-Gag expression in the presence of the anti-retroviral drugs, indicating that viral release
without outgrowth was not a significant contributor to the increased frequency of HIV-1-Gag
+ detection in the dQVOA.
Effector memory differentiation lowers variability in measured reservoir
frequencies
Viral outgrowth assays typically employ target cells to support virus expansion using activated
allogeneic lymphoblasts or permissive cell lines [37, 67–70]. However, the HIV-infected indi-
vidual’s own CD4+ T cells may generally represent a target cell population that can more effec-
tively replicate virus than allogeneic HIV-naïve donor lymphoblasts. To examine this
question, we performed parallel QVOA using the standard QVOA conditions, dQVOA with
target lymphoblasts added, and dQVOA (no target lymphoblasts added) on resting CD4+ T
cells from three independent participants in this study (S2 Fig). In a comparison between
dQVOA with and without added target lymphoblasts, two of the three participant samples
showed a small increase in IUPM when no target lymphoblasts were added to the cultures, but
these differences were not statistically significant. In one donor (NIH 2–20), the addition of
target lymphoblasts showed a small increase in IUPM when allogeneic target lymphoblasts
were added, but again overlapping confidence intervals suggest this difference is not statisti-
cally significant. By contrast, dQVOA IUPM values obtained either with or without addition
of activated target lymphoblasts resulted in a higher reservoir frequency than standard QVOA,
including one donor from which no measurable replication-competent virus could be detected
even with repeated attempts using standard QVOA conditions (NIH 2–20; S2 Fig). Together
these data suggest that while the participant’s own activated CD4+ T cells may provide a slight
growth advantage to some proviruses, overall the dQVOA supports more favorable conditions
to induce virus expression.
Studies of the HIV-1 reservoir have shown that a significant proportion of integrated provi-
ruses detected using PCR-based approaches are genetically defective, resulting from accumula-
tions of reverse transcription errors and G-to-A mutations induced by APOBEC3G [47, 71].
Consequently, the frequency of replication-competent HIV-1 provirus is significantly lower
Effector memory differentiation increases reactivation of HIV-l
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than the frequency measured in PCR-based assays. However, the QVOA has been demon-
strated to under-represent the HIV-1 reservoir due to stochastic induction of latency reversal
in the context of mitogen-directed activation of rCD4+ T cells [47]. Transcriptionally-quies-
cent subsets like TCM may harbor intact proviruses at genomic locations influenced by epige-
netic modifications that are repressive to HIV-1 expression. Sequestration of transcription
factors may also ultimately limit the propagation of infectious HIV-1 using standard in vitro
culture stimuli [72]. CD4+ T cell phenotype during initiation of culture conditions in assays
like QVOA may heavily influence the qualitative and temporal responsiveness to stimulation,
leading to an apparent stochastic latency reversal frequency that leaves many intact proviral
genomes uninduced [47]. Indeed, replicate QVOA (n = 7) using the same peripheral blood
sample from RAVEN participant 2147-R in the context of PHA plus IL-2 activation alone
showed a half-log range in IUPM frequencies (0.054–0.275 IUPM) with a high coefficient of
variation (62.12%; Fig 2A), suggesting an inherent variability in the ability to reproducibly
induce HIV-1 expression and viral outgrowth [69]. By contrast, inducing effector memory dif-
ferentiation prior to activation in dQVOA not only revealed a significantly higher replication-
competent reservoir frequency in this participant (2.524–2.821 IUPM; Fig 2A), an 18-fold
increase in the latent reservoir size, but this increase was coupled with a 10-fold lower coeffi-
cient of variation (6.21%). An advantage of an increased frequency of positive wells observed
in dQVOA (Fig 1E) is the reduction in the coefficient of variation that is generated through
the maximum likelihood calculation. Together, these data demonstrate that driving effector
memory differentiation supports more reproducible HIV-1 reactivation, thus reducing reli-
ance upon stochastic mechanisms to induce HIV-1 expression.
Previous studies have suggested that γ-chain cytokines like IL-7 alone induce homeostatic
proliferation, but have reported conflicting abilities to reactivate latently-infected memory
CD4+ T cells [73–75], whereas IL-15 is a known inducer of latency reversal [76]. The collec-
tion of supernatant samples from dQVOA prior to PHA plus IL-2 activation allowed us to
assess whether differentiation with a combination of γ-chain and DC-derived cytokines alone
was sufficient to induce efficient latency reversal in rCD4+ T cells (Fig 1D; Fig 2B). We deter-
mined the frequency of positive wells at the top assay dilution from three participants in the
RAVEN cohort after 7 days of differentiation culture and again after PHA activation and an
additional 11 days of outgrowth, and compared these values to the frequency of positive wells
at the top assay dilution generated in QVOA with PHA plus IL-2 activation alone (up to 20
days of outgrowth after PHA activation). Interestingly, we observed detectable p24 positive
wells in all participants after differentiation culture alone in dQVOA (Fig 2B). Culturing differ-
entiated rCD4+ T cells after activation further increased the number of wells exhibiting expo-
nential viral outgrowth over differentiation alone in all 3 participants, resulting in a
consistently higher measured reservoir frequency than observed from the QVOA. These
results suggest that exposure to γ-chain and DC-derived cytokines alone in vitro can induce
HIV-1 expression from latently-infected cells but is insufficient for latency reversal of a pro-
portion of the latent reservoir unless coupled with an activating signal.
dQVOA IUPM correlate with key clinical parameters of HIV pathogenesis
We next determined if the frequency of the HIV-1 reservoir in dQVOA correlated with
measured clinical parameters in the RAVEN and NIH cohorts (Fig 3A). We performed
cross-correlation linear regression analyses between participant age, duration of viral suppres-
sion under therapy, nadir CD4+ T cell count prior to ART initiation, CD4+ T cell count and
CD4+:CD8+ T ratio at time of leukapheresis, and the highest viral load (VL) reported prior to
initiation of ART. The dQVOA IUPM frequency in these participants correlated with that
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from QVOA (Spearman r = 0.85, p = 0.0004), supporting a relationship between the
measured reservoir that is reactivated through activation alone and the reservoir size that is
detected through effector memory differentiation pathways (Fig 3A and 3B). The IUPM fre-
quency in rCD4+ T cells after dQVOA correlated with the highest reported pre-ART VL
(Spearman r = 0.92, p = 6.3x10-5), suggesting higher VL prior to treatment results in greater
seeding and/or retention of replication-competent provirus after initiation of ART (Fig 3A
and 3B).
The magnitude of the latent replication-competent reservoir measured in dQVOA was
compared to ex vivo lymphocyte, rCD4+ T cell, and post-differentiation parameters by linear
regression (Fig 3C). The frequency of cells in the TEM subset in the rCD4+ T cell population
correlated with dQVOA IUPM (p = 0.013), though the TEM subset in the ex vivo population
Fig 2. Ex vivo differentiation drives HIV-1 reactivation in a reproducible manner. a, Column plot showing the measured IUPM for QVOA
(n = 7) and dQVOA (n = 3) performed on RAVEN participant 2147-R. Error bars are 95% confidence intervals generated by the program
IUPMStats (http://silicianolab.johnshopkins.edu). %CV represents the coefficient of variation for each assay type. (p = 0.0004; unpaired t test
with Welch’s correction). Black brackets indicate assays initiated on the same day and performed in parallel. %CV over each bracket represents
the %CV for each batched assay set-up. b, Column plots showing the frequency of p24 positive wells after complete QVOA (left panel, white
bars), differentiation alone as part of dQVOA (right panel, black bars), or after differentiation, activation, and outgrowth in complete dQVOA
(right panel, white bars). For both panels, gray bars indicate the frequency of wells that remain p24 negative after completion of each assay.
Frequency of HIV-1-Gag+ wells was determined using the top assay dilution for each assay.
https://doi.org/10.1371/journal.ppat.1008074.g002
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Fig 3. Reservoir measurements derived from dQVOA directly correlate with QVOA, pre-ART highest viral load reported, and effector memory T
cells. a, The cross-correlation matrix (Pearson r value) of clinical measurements from linear regression. Analysis includes all available data from
participants across the NIH and RAVEN cohort. ��� denotes p< 0.001. b, XY Graphical representation of correlations found to be significant in panel a. c,
Correlation with dQVOA IUPM from linear regression (Pearson r value) for each individual measurement. Analysis includes available data from
participants in the RAVEN cohort. � denotes p< 0.05; �� denotes p< 0.01; ��� denotes p< 0.001.
https://doi.org/10.1371/journal.ppat.1008074.g003
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did not correlate with statistical significance. These results are consistent with observations
that the TEM subset is a significant source of infected cells with intact proviruses [19, 77]. The
dQVOA reservoir size also correlated with several post-differentiation populations: the CD3
+CD25+ compartment (p = 0.0389), and the TEM and TEMRA subsets (p = 0.002 and
p = 7.58x10-6 respectively). These data support that both activation and effector memory dif-
ferentiation are key correlates of latency reversal in rCD4+ T cells. Indeed, the fold-change in
frequency of the CD25+TTM and CD25+TEM compartment also exhibited significant correla-
tion with dQVOA IUPM (p = 0.0182 and p = 0.0427 respectively). Identifying these correlates
of latency reversal provides the basis for mechanistic understanding of factors that govern the
replication-competent HIV-1 reservoir both in vitro and in vivo.
dQVOA reveals population of expanded proviral clones in rCD4+ T cells
To characterize the viral variants induced by differentiation in dQVOA, we performed single-
genome sequencing on viral RNA found in the HIV-1-Gag+ supernatants from 3 participants
(Fig 4)[78]. We obtained 67 virus sequences from NIH participant 2–20, 184 from NIH partic-
ipant 2–37, and 131 from RAVEN participant 2147-R. These data demonstrate that multiple
variants, including probable expanded clones, were expressed from the rCD4+ populations,
further supporting that differentiation conditions are inducing the expression and outgrowth
of a repertoire of replication-competent HIV-1. Single-genome sequencing was performed
using the P6-PR-RT primer set, which has been demonstrated previously to have a high clonal
prediction score for accuracy in identifying clonal expansion in viral outgrowth assays when
used on samples from donors with high HIV diversity [9, 79]. Strikingly, in the sampling per-
formed as part of SGS analysis, each participant showed evidence of identical sub-genomic
sequences across different dQVOA wells, suggesting that these sequences may have resulted
from induction of replication-competent provirus in expanded T cell clones in vivo. These
data are in agreement with several recent studies suggesting one mechanism contributing to
HIV-1 persistence in vivo is homeostatic proliferation of infected memory CD4+ T cells result-
ing in clonal expansion [80–84]. Of note, identical sequences within dQVOA wells likely result
from a single infected cell that was induced to expand and produce virus particles ex vivo and
are not indicative of clonal expansion in vivo. In addition to the observation that identical
sequences were found across different dQVOA wells, we also observed sequences that were
different by 1–2 nucleotides from the consensus within each dQVOA well. These minor varia-
tions are a strong indicator of viral replication in the assay as expected.
Discussion
The mechanisms responsible for the persistence of the latent HIV-1 reservoir in memory CD4
+ T cell subsets in vivo are still being investigated, which has hindered design of effective eradi-
cation strategies. Data from SIV-infected macaques demonstrated that the viral reservoir is
present in TCM and TTM residing in lymph nodes and gastrointestinal mucosa by day 3 post
infection, suggesting seeding of the reservoir in these subsets is a very early event in infection
that persists after introduction of ART [3]. Treatment interruption studies also have demon-
strated viral rebound emerges from a limited pool of latent viruses, with the potential sources
of rebound viremia observed after different therapeutic interventions still under investigation
[6, 83, 85, 86]. The proposed dynamics of HIV-1 reservoir reactivation in vivo include the TCR
recognition of cognate antigen by latently HIV-1-infected memory CD4+ T cells through pre-
sentation by APCs, which triggers proliferation and effector memory differentiation [87, 88].
The TCM subset is characterized by a delay in production of any prototypic cytokines of the
effector lineage after TCR stimulation, a process that initially favors proliferation over
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Fig 4. Differentiation drives reactivation of clonally-expanded, replication-competent HIV-1. P6-PR-RT single-genome sequencing[78] was performed on HIV-
1-Gag+ culture supernatants from dQVOA on NIH participant 2–20 (n = 2), NIH participant 2–37 (n = 1), and RAVEN participant 2147-R (n = 1). Circles represent
single RNA genomes in the supernatants. Sequences obtained from different wells are shown in different colors. Identical sequences across different wells may result
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differentiation (reviewed in [87]). Activation alone may not effectively differentiate TCM to
acquire effector function. Indeed, a previous study observed the TCM subset to be heterogenous
in the ability to differentiate and express effector cytokines when activated in non-polarizing
conditions in vitro [89]. Half of clonal TCM populations activated in vitro proliferated in the
absence of effector differentiation while other the other half spontaneously differentiated to
IFN-γ - or IL- 4-producing cells in the non-polarizing activating conditions through a bona
fide stochastic process [89]. Significantly, acetylation profiles of cytokine gene regions showed
contrasting patterns in TCM and TEM subsets during in vitro non-polarizing activation condi-
tions, with the TCM subset showing hypoacetylation and TEM showing polarized acetylation
profiles that correlated with the expression of effector cytokines, supporting the conclusion
that TCM and TEM subsets to have differential epigenetic profiles that regulate gene function
[89]. Recent studies showed a significant correlation between latency reversal and the upregu-
lation of effector function associated with differentiation. Latency reversing agents that trig-
gered quiescent TCM and TTM to pathways of differentiation correlated with the highest levels
of latency reversal [49].
Here, we employed novel enhancements to the previously established QVOA platform to
show effector memory differentiation in the presence of γ-chain and DC-derived cytokines
significantly induced HIV-1 latency reversal from rCD4+ T cells when coupled with sequential
mitogen stimulation and IL-2 exposure. γ-chain cytokines mediate homeostatic proliferation
of the TCM and TEM subsets that drive proliferation and maintenance of long-term memory in
vivo, and exposure to these cytokines can mediate latency reversal in some contexts [73–76].
DC cytokines are known to upregulate the expression of the IL-2/IL15Rβ and γ-chain [90, 91],
which supports the CD4+ T cell response to γ-chain cytokines. The level of upregulation of
these receptors was comparable to that induced by TCR stimulation, while naïve and memory
subsets also were shown to express IL-7R alpha [65]. The DC cytokines also promote greater
responsiveness to IL-2, corresponding to the upregulation of IL-2Rα expression we observed
in dQVOA. The differentiation effect of γ-chain and DC-derived cytokines is coupled with
pro-survival mechanisms such as the upregulation of Bcl-2 that protects T cells from apoptosis
[92], thus helping to preserve the viability of cells during differentiation. In vivo, pro- and anti-
inflammatory signaling pathways mediated by γ-chain and DC-derived cytokines have been
shown to effect reservoir size during the establishment of HIV-1 infection [93]. Other cyto-
kines, such as IL-4 and IL-12, which polarize memory CD4+ T cells, may also be employed to
induce differentiated subsets that have been shown previously to support high levels of virus
production and reverse latency in vitro [40, 94]. dQVOA results from two participants, 3068-R
and 2026-R, exhibit both a high frequency of the reservoir and cells in the naïve T subset.
Recent studies have shown the CD4+ naïve population may contribute significantly to the rep-
lication-competent reservoir in vivo [95, 96]. Naïve CD4 T cells have been shown to proliferate,
upregulate expression of γ-chain cytokine receptors, and express effector cytokines in response
to differentiation, albeit to a more limited extent than the TCM subset [65]. These induced
pathways also may prime the naïve CD4 T cells to support HIV expression during activation.
Alternatively, if the naïve CD4+ T cell population induces robust HIV latency reversal through
mitogen activation, the standard and differentiation QVOA conditions both use PHA plus IL-
2 stimulation in the presence of allogeneic feeder cells to support the induction of HIV expres-
sion. Future studies will examine the memory subset-specific effect of differentiation and
polarization on latency reversal and characterize mechanisms of HIV-1 persistence.
from latency reversal of infected cell clones. Sequences within wells that are different by a single nucleotide or two from a large rake of identical sequences are likely
the result of RT error upon viral replication in the QVOA wells rather than from induction of different proviral variants.
https://doi.org/10.1371/journal.ppat.1008074.g004
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The presence of DC derived cytokines enhances the homeostatic proliferation effect of the
gamma chain cytokines, and we expect CD4+ T cells to expand in response to differentiation
cytokines. However, proliferation alone is not effective at inducing HIV expression. Moso
et al. recently demonstrated HIV latency is effectively maintained in proliferating cells [97].
Interestingly, Vandergeeten et al. also showed that the γ-chain cytokine IL-7 does not induce
HIV latency reversal in latently infected cells, but can support enhanced HIV expression when
the cells are productively infected [74]. Therefore, we would not expect the differentiation step
to be a significant driver of latency reversal through proliferation. However, one explanation
to the observation of a detectable frequency of HIV post-differentiation (Fig 2B) is that cells
with a baseline low level expression of HIV transcripts may be induced into virus production
in the presence of IL-7, which in the anti-viral free context of the culture conditions would
result in virus propagation and spreading infection to neighboring CD4+ T cells.
Standard QVOA culturing conditions [67] utilize multiple rounds of cellular activation to
induce latency reversal. HIV-infected participant derived resting CD4+ T cells initially are
introduced into culture with PHA plus IL-2 in the presence of irradiated allogeneic feeder cells
from a mixture of two HIV-naïve donors. The following day, a second activation is induced by
the addition of activated allogeneic target cells from four unrelated HIV-naïve donors in the
presence of high levels of IL-2 (100 U/mL). Alloreactivity is a well-established method of cellu-
lar activation, including the memory T cell compartment [98]. Standard QVOA cultures are
then subsequently stimulated one more time by the addition of activated allogeneic target cells
from a mixture of four additional unrelated HIV-naïve donors on day 8, for a total of 3 rounds
of repeated activation of the HIV-infected CD4+ T cell population. dQVOA culture conditions
initiate differentiation cytokine culture on day -7, and PHA plus IL-2 activation in the pres-
ence of irradiated allogeneic feeder cells from a mixture of two HIV-naïve donors on day 0. No
activated allogeneic target cells are added at any point in the culture to induce a third round of
activation. The standard QVOA conditions maintain continued and supported activation for
almost three weeks in culture and as demonstrated previously fail to effectively induce HIV
latency reversal in a significant fraction of the CD4+ population infected with intact provirus
[47], and indeed recent attempts to increase the assay sensitivity relies upon long term
repeated restimulation to capture the inducible intact proviral reservoir (MS-VOA [48]).
Differentiation is a biological pathway in response to DC signaling aimed at inducing effec-
tor cells, including the expansion of the effector cell population, which are part of the required
adaptive immune response. T cell differentiation results in the upregulation of the expression
of transcription factors such as NF-AT, NF-KB and AP-1, all factors previously identified to be
associated with HIV expression [51, 99, 100]. These transcription factor complexes are
involved in chromatin remodeling and expression of lineage specific cytokines [101]. We com-
pare activation alone (standard QVOA) to the combination of differentiation followed by acti-
vation (dQVOA) to understand how differentiation signals influence HIV latency reversal. We
find that polarizing resting CD4+ T cells through effector differentiation followed by mitogen
activation results in a higher frequency of HIV latency reversal, as measured by a significantly
increased IUPM. The combination of proliferation, activation and acquisition of effector func-
tion that directly result from differentiation may all contribute specifically to the ability of rest-
ing CD4+ T cell populations to support the induction of HIV expression that cannot be as
effectively obtained upon mitogen stimulation alone. Interestingly, although we observed an
increased IUPM frequency in all participants with a detectable replication-competent reservoir
(Fig 1F), the fold increase was variable. This observation may reflect the dynamics of the reser-
voir within each individual, which includes factors such as the prevalence of expanded clones
and immunological signatures that stabilize the reservoir. Future studies will examine the
influence of inflammatory signatures that drive HIV persistence in different resting CD4+ T
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cell subsets, and how these signatures may influence APC differentiation responses. Together,
these data demonstrate the impact of differentiation over activation alone for efficient latency
reversal, specifically in the context of the HIV-1 latent reservoir, and provide mechanistic
insight into the stochastic reactivation observed in QVOA. Further characterizing these mech-
anisms will provide the basis for understanding the dynamics that influence latency reversal in
highly-quiescent, memory CD4+ T cell compartments in vivo, as well as identifying potential
mechanisms for viral rebound during treatment interruption.
Quantifying the number of cells harboring latent, replication-competent HIV-1 provirus is
critical to evaluating cure strategies, but the low frequency and accumulation of inactivating
mutations makes precise quantification extremely challenging through molecular-based
approaches. Our data demonstrates that differentiation of rCD4+ cells prior to QVOA is an
effective tool for promoting latency reversal in vitro, which enhances the performance of exist-
ing protocols to quantify the frequency of replication-competent HIV-1 in rCD4+ T cells from
virally-suppressed individuals. Results from recent assays quantifying the intact proviral reser-
voir have suggested the frequency of non-mutated genomes is much higher than what has
been estimated by viral outgrowth [102]. However, numerous host cell as well as virologic fac-
tors may contribute to viral replication fitness in vivo, and understanding the mechanisms that
direct HIV expression from latently infected cells remains a critical component both in reser-
voir quantification and studying HIV persistence. For the first time, ex vivo effector memory
differentiation has moved reservoir measurements closer toward what may be the bona fide
replication-competent reservoir frequency, thus beginning to bridge the gap between out-
growth and molecular-based quantification. Taken together, these data support accumulating
evidence that effector memory differentiation is a key pathway to HIV-1 latency reversal that




PBMC samples were obtained from 12 HIV-1 infected, virally suppressed adult male partici-
pants of two established study cohorts. Two participants were in the NIH cohort Analysis of
HIV-1 Replication During Antiretroviral Therapy (AVBIO2, protocol 08-I-0221) and ten par-
ticipants were in the HIV Reservoir Assay Validation and Evaluation Network (RAVEN)
cohort. All participants initiated ART during chronic infection and exhibited viral suppression
in plasma HIV-1 VL (<40 copies/mL) for greater than 10 years. Plasma HIV-1 VL and T cell
measurements were performed at each study visit.
Ethics statement
The NIH study was approved by the NIAID institutional review board (IRB FWA#00005897)
and the RAVEN cohort was approved by the UCSF Committee on Human Research (IRB
#10–03244). RAVEN participants are enrolled and followed as part of the UCSF OPTIONS
and SCOPE programs with specific consent for apheresis collections and testing for this study.
All participants were adults (>18 years of age) and provided written, informed consent.
QVOA
QVOA was performed as previously described with minor revision[67]. Briefly, cryopreserved
PBMC from HIV-1-infected participants were thawed and cultured overnight in complete
media (RPMI-1640 with Glutamax(Gibco, 61870–036) containing 10% heat-inactivated fetal
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bovine serum (Peak Serum, PS-FB1), 1% penicillin and 1% streptomycin (Gibco, 15140–122)).
Cells were enriched for rCD4+ T cells through negative, magnetic bead separation (StemCell,
17962 and 19250) and assessed for purity and memory T cell subsets by flow cytometric analy-
sis. rCD4+ T cells were plated at 1x106 cells per well (A dilution), 2x105 cells per well (B dilu-
tion), and 4x104 cells per well (C dilution) in complete media with the addition of 100 IU/mL
recombinant human IL-2 (R&D Systems, 202-IL), 1–1.2% T cell growth factor (TCGF) pre-
pared as described previously[67], and 0.5 μg/mL PHA (ThermoFisher Scientific, Remel,
R30852801). γ-irradiated allogeneic PBMC were added at a 10:1 ratio. Following overnight
incubations, PHA was diluted in the cultures through media replacement and CD8-depleted
(ThermoFisher Scientific, 11147D) lymphoblasts were added as targets for viral expansion.
Media and cells were replenished and replaced according to previous publication and main-
tained for up to 20 days. All supernatants removed for nutrient supplementation were tested
for the presence of p24 antigen by ELISA (PerkinElmer, NEK050B001KT) according to the kit
protocol. Wells were considered positive for HIV-1 outgrowth if the p24 concentration was
above 3.25 pg/mL. IUPMStats v1.0 was used to calculate the frequency of latently infected,
induced rCD4+ T cells[66].
Differentiation QVOA (dQVOA)
A detailed protocol can be found on protocols.io [103]. As described above for QVOA, cryo-
preserved PBMC were thawed, rested overnight, and magnetically enriched for rCD4+ T lym-
phocytes following manufacturer protocol (StemCell, 17962 and 19250). For all RAVEN
participants, QVOA and dQVOA were initiated in parallel from the same original pool of
rCD4+ T cells. After magnetic enrichment and before differentiation, rCD4+ T cells were
diluted and plated at 5x105 cells per well (A dilution), 2x105 cells per well (B dilution), 4x104
cells per well (C dilution), and 8x103 cells per well (D dilution) in complete media containing
25 ng/mL each of TNF-α, IL-6, IL-7, IL-10, and IL-15 (R&D Systems, 210-TA, 206-IL, 207-IL,
217-IL, 247-ILB respectively). Media and cytokines were replenished every 3–4 days by replac-
ing half of the media without disturbing the cellular layer. After 6–7 days of differentiation and
without removing exogenous cytokines, individual wells were stimulated with 0.5 μg/mL
PHA, 100 IU/mL IL-2, and γ-irradiated allogeneic PBMC at a 10:1 ratio. Following overnight
incubation, PHA concentrations were reduced through replacement of stimulation media
with complete media containing 100 IU/mL IL-2 in cultures. Cultures were replenished every
3–4 days by replacing half of the complete media containing 100 IU/mL IL-2 without disturb-
ing the cellular layer. As with QVOA, all supernatants from media replenishment and end of
assay time points were tested for the presence of p24 antigen by ELISA (PerkinElmer,
NEK050B001KT) according to the kit protocol and IUPMs were calculated with IUPMStats
v1.0[66].
Flow cytometry
During rCD4+ T cell enrichment and differentiation, cells were assessed for memory pheno-
type through flow cytometric analysis and as previously published [65]. The antibodies were
obtained from Biolegend unless otherwise noted: CD3 (HIT3a, Pacific Blue, 300330), CD4
(RPA-T4, Brilliant Violet 510, 300546), CD8 (SK1, PerCP-Cy5.5, 344710), CD16 (eBioscience,
eBioCB16, FITC, 11-0168-42), CD24 (eBioscience, eBioSN3 A5-2H10, FITC, 11-0247-42),
CD25 (BD Biosciences, M-A251, APC, 555434), CD45RA (HI100, APC-Cy7, 304128), CD27
(BD Biosciences, L128, PE, 340425), CCR7 (BD Biosciences, 3D12, PE-Cy7, 557648). A lineage
(Lin) cocktail included antibodies against CD16 and CD24. Cell viability was assessed via the
use of a Live/Dead viability kit (Invitrogen, FITC, L34970). Data was collected with a
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Stratedigm S1000Exi flow cytometer and analyzed on FlowJo v10.0 software (BD Biosciences).
RCD4+ T cells were identified as CD3+CD8–Lin–CD25–. Naïve CD4+ T cells were identified
as CD3+CD8–Lin–CD45RA+CCR7+CD27+. TCM were identified as CD3
+CD8–Lin–C-
D45RA–CCR7+CD27+. TTM were identified as CD3
+CD8–Lin–CD45RA–CCR7–CD27+. TEM
were identified as CD3+CD8–Lin–CD45RA–CCR7–CD27–. TEMRA were identified as
CD3+CD8–Lin–CD45RA+CCR7–CD27–.
Single genome sequencing
Single-genome sequencing (SGS) of a portion of p6-PR-RT was performed as previously
described [9]. Sequences were aligned using ClustalW. Neighbor-joining phylogenetic analyses
were performed using MEGA7.
Statistical analyses
Due to differing antibody panels and flow cytometric gating strategies, NIH2-20 and NIH2-37
were excluded from correlation analyses involving T cell subsets. When an assay failed to yield
a p24 positive well, the assay-specific maximum likelihood value for zero positive wells was
used in statistical analyses. Wilcoxon matched-pairs signed rank and t tests were performed
with GraphPad Prism version 8.0.0. Correlation analyses were carried out using Python v.3.3.1
with the Scipy v.1.1.0 library using the Pearson correlation coefficient (r value). Statistical sig-
nificance of linear regression was determined using the two-sided hypothesis Wald Test with
t-distribution built in to the Scipy linregress module. Sequence Overrepresentation (SOR)
Index was determined using the tool available at (https://michaelbale.shinyapps.io/prob_
identical/).
Supporting information
S1 Fig. Ex vivo effector memory differentiation upregulates CD25 expression on all mem-
ory T cell subsets in dQVOA. a, Column plot showing CD25 expression on either naïve or
memory T cell subsets. Wilcoxon matched-pairs signed rank tests were used and �� denotes
p< 0.01. b, Column plots showing percentages of memory T cells staining positive for IFN-g
+, IL-4+ and IFN-g+/IL-4+ and the fold-increases of the percentage memory T cells expressing
CCR5+ after differentiating for 7 days. Samples were evaluated from three separate uninfected
(UI) and HIV-1-infected, virally suppressed individuals (HIV+) according to previous publi-
cation [65]. Each independent sample is shown, with the grand mean and standard deviation
shown. Wilcoxon matched-pairs signed rank tests were used and NS denotes insignificant dif-
ferences between groups.
(TIF)
S2 Fig. dQVOA generates higher IUPM values with or without target lymphoblast addi-
tion. rCD4+ T cells from 3 independent virally suppressed participants were evaluated using
standard QVOA (red circles), dQVOA + lymphoblast targets (blue squares), and dQVOA (no
lymphoblast targets added; green triangles) to generate IUPM values. Error bars represent 95%
confidence intervals. BD = below detection.
(TIF)
S1 Table. Frequency of HIV-GAG+ wells in each dilution. Number of p24+ positive wells
over the total number of wells plated per assay is shown for dQVOA (grey banded rows) versus
QVOA (white banded rows). 1Dilution A in QVOA is 1x106 rCD4+ T cells per well and
dQVOA is 5x105 rCD4+ T cells per well. Dilutions B through E are consistent between the two
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assays. NA, not applicable.
(PDF)
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